DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

Montrouge, France, February 20 2024

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced two presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting, February 23-26 in Washington, D.C.

A poster presentation by David Fleischer, M.D. of Children’s Hospital Colorado will describe the long-term (five-year) safety results of epicutaneous immunotherapy (EPIT) with Viaskin Peanut in peanut-allergic children aged 4-11 years in the PEOPLE (PEPITES Open-Label Extension) Phase 3 study.

An oral presentation, in collaboration with Icahn School of Medicine at Mount Sinai and Beckman Coulter Life Sciences, will describe how the immune modifying effects of Viaskin Peanut treatment over time were characterized in toddlers using a streamlined, novel approach to basophil activation testing (BAT) during the multicenter Phase 3 EPITOPE trial of in children aged 1-3 years.

DBV is sponsoring a non-CME Product Theater titled “Importance of Early Intervention for Peanut Allergy.” Professors Hugh Sampson, M.D. and Julie Wang, M.D., of the Icahn School of Medicine at Mount Sinai, and David Fleischer, M.D., of Children’s Hospital Colorado, will discuss the clinical benefits of early treatment initiation for peanut allergy through case-based learning. The panelists will also address how they navigate the shared decision-making process with families soon after a peanut allergy diagnosis, including factors related to clinical trial participation, such as eligibility and understanding barriers to enrollment. The Product Theater is scheduled for Saturday, February 24, from 10:00 a.m. to 10:30 a.m. EST in the Walter E. Washington Convention Center, Level 2, Hall D.

DBV is proud to sponsor the AAAAI Fellows-in-Training (FIT) Program reception on Friday, February 23. The private reception welcomes current allergy/immunology Fellows-in-Training.

DBV will host a booth (#567) in the AAAAI exhibit hall where attendees can learn more about epicutaneous immunotherapy with Viaskin, including our ongoing clinical trials in peanut-allergic children.

“The five-year safety data from our PEOPLE open-label extension study of Viaskin Peanut in children aged 4-11 years demonstrate that the long-term safety profile of Viaskin Peanut 250 μg is consistent with safety results observed in shorter (one-year, three-years) treatment periods,” said Pharis Mohideen, M.D. Chief Medical Officer at DBV Technologies.